Industry Insights
Latest in gene therapy and rare disease
iRegene Therapeutics’s NouvSight001 Cleared for Clinical Trials in the U.S. and China for Retinitis Pigmentosa
Following its Parkinson’s disease program, iRegene advances another off-the-shelf cell therapy into clinical development in the U.S. and China.
Parkinson’s-focused Aspen and bispecific biotech Bambusa plan IPOs
Parkinson’s disease cell therapy-focused Aspen Neuroscience and bispecific biotech Bambusa Therapeutics are the latest drug developers to eye up a public listing.
Cell Therapy Manufacturing Takes Shape Across Asia-Pacific
Cell and gene therapy is accelerating across Asia-Pacific, but manufacturing remains fragmented. Strategic automation, adaptable bioprocessing platforms, stronger supply chains, and workforce developm
Contracting Expansion: A Path to Better CAR T-Cell Therapy Production
Shorter cell expansion steps could significantly accelerate CAR T-cell therapy production processes, according to researchers, who cite microfluidic culture systems, real-time PAT tools, and AI-enable
StockWatch: Caribou Plunges as It Pursues Strategic Alternatives
Caribou has halted trials of vispacabtagene regedleucel (vispa-cel, formerly CB-010) a treatment for relapsed or refractory B cell non-Hodgkin lymphoma; and of CB-011, an allogeneic anti-BCMA CAR-T ce